Condition: Hyperlipidemia · Ursodeoxycholic Acid · Statin Therapy · Sponsor: First Affiliated Hospital Xi'an Jiaotong University
The purpose of this clinical trial is to understand whether the drug Ursodeoxycholic acid (UDCA) can prevent glucose intolerance in participants with hyperlipidemia who are taking statins. It will also assess the safety of UDCA. The primary questions it aims to answer are: * Will UDCA reduce the incidence of glucose intolerance in participants taking oral statins? * Will the use of UDCA decrease other adverse events in patients taking oral statins? Participants will: * Take Atorvastatin combined with UDCA or a placebo daily for 6 months * Have follow-up visits on day 40, day 110, and day 180 Have their examination indicators recorded.
This description comes directly from the study's public registry record.
Yue Yu · 0086-85323810 · yueyu05@163.com
Yue Wu, Professor · 0086-029-8532-3664 · imyuewu@qq.com
Always discuss trial participation with your own doctor first.
| Department of Cardiology, First Affiliated Hospital of Xi'an Jiaotong University | Xi'an, Shaanxi, China | Recruiting |
| The First Affiliated Hospital of Xi 'an Jiaotong University | Xi'an, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06684106